Zantac

Joseph Bayer, the plaintiff in the first case surrounding GSK’s Zantac has voluntarily dismissed his case against the company, citing personal health reasons. Bayer sued GSK and several others for esophageal cancer he developed that he and his care team attributed to the drug. So far, he has gotten a combined settlement of half a million dollars from the other companies. The dismissal isn’t a true win for GSK, however, as Bayer has a year to refile the case.